The anti-acetylcholine potency of a number of anti-Parkinsonism drugs and related phenQthiazine compounds was determined using the isolated guinea-pig ileum. The antagonism was assessed by the difference between the pA2 and pAio values and by log concentration-response curves for acetylcholine in presence and absence of the antagonists. All compounds except chlorpromazine showed some evidence of competitive antagonism to acetylcholine. The anti-tremor potency of the compounds was assessed from suppression of Tremorine-induced tremors in mice. There was a relation between anti-acetyIcholine and anti-Tremorine potency among the antiParkinsonism drugs, but not among the phenothiazine compounds. Some implications of the findings are discussed in relation to the mode of action of anti-Parkinsonism drugs.
of 2.5 ml. capacity, was manually operated. Its contents were changed by upward displacement and overfow without exposing the preparation to air. Aerated Tyrode solution at 370 was used.
Assessment of type of antagonism. Two criteria were used to assess whether or not the antagonism to acetylcholine was competitive. First, when the difference between pA2 and pAjo did not differ significantly from 0.95 at the 5% level, the antagonism was considered to be competitive. If the difference was significantly less than 0.95 (P<0.05), the antagonism was assumed to be non-competitive (Marshall, 1955a) . Second, competitive antagonism was indicated by statistically significant parallelism between the log concentration-response curves plotted for acetylcholine alone and in the presence of the antagonist after conversion to linear form as described by Timms (1956) and the ability to achieve maximum contraction in the presence of the antagonist. The curves were plotted in the presence of two concentrations of each antagonist, approximating to the pA2 and pAio concentrations respectively. To test for parallelism, the curves were converted to linear form by plotting probits of the percentage of maximal contraction against log concentration of acetylcholine. The regression coefficients were calculated, and, if these did not differ significantly (P<0.05), the two curves were considered to be parallel.
Measurement of anti-tremor potency. Anti-tremor potency was measured by a mouse protection test against tremors produced by the compound Tremorine (1,4-dipyrrolidin-l'-ylbut-2-yne). Albino mice weighing 20 to 30 g were used. Food and water were removed from the cages 30 min before the experiments, which were carried out at room temperature. Groups of 5 or 10 mice were used and each received a dose of 30 mg/kg of Tremorine intraperitoneally. This dose caused severe tremor, together with profuse salivation and lacrimation. Aqueous solutions of the anti-tremor drugs were prepared so that 0.2 ml./25 g body weight could be given subcutaneously 30 min before the dose of Tremorine, and their potency was assessed by observing the percentage of mice in each group which showed tremor of the head, body, limbs and tail. For each drug, the dose which would reduce the incidence of Tremorine-induced tremor to 50% was calculated by the method of Miller & Tainter (1944) . This dose was termed the ED50 value. and the type of antagonism was assessed according to the method of Marshall (1955a) . pA determinations of other workers for some anti-Parkinsonism drugs, summarized in Table 3 , are in good agreement with our results. The drugs could be divided into four groups when the type of antagonism was assessed on the basis of log concentration-response curves.
(1) Drugs which altered neither the slope nor the maximum contraction attainable at either the pA2 or pA1O concentration, namely, hyoscine, atropine, benztropine, cycrimine, benzhexol, procyclidine, ethopropazine and caramiphen ( Fig. 1 (1) ).
(2) Drugs which, at pAO but not the pA2, concentration, depressed the maximum contraction but not the slope between 20 and 70% of the maximal unantagonized contraction, namely, promethazine, RP 6415 and RP 6788 ( Fig. 1 (2) ). (3) Drugs which reduced both the slope and the maximum contraction at the pA10, but not at the pA2, concentration, namely, diphenhydramine, diethazine, benactyzine, RP 6549, RP 7185, RP 7044, RP 6778 and RP 6743 ( Fig. 1 (3) ).
(4) Drugs which reduced the slope and the maximum contractions at both pA2 and pA10 concentrations, namely, chlorpromazine ( Fig. 1 (4) ).
The type of antagonism as derived from statistically significant or non-significant parallelism (at the 5% level) between the unantagonized acetylcholine curve and the curves in presence of pA2 and pA10 concentrations after conversion to the linear form is also given in the last column in Table 2 .
Anti-tremor potency. The anti-tremor potencies of the drugs against Tremorineinduced tremors in mice are given in Table 4 . Comparison of Tables 4 and 2 shows that, when anti-Parkinsonian drugs are arranged in order of decreasing anti-tremor Table 2 ). Abscissa: anti-Tremorine potency, ED50 (mg/kg) (from Table 4 ). Correlation coefficient, r=0.67, P<0.01.
DISCUSSION
Investigations of the kinetics of drug antagonism serve only to emphasize the difficulty of determining precisely whether or not an antagonist is acting competitively. We have used two criteria, the concentration-response curve and the (pA2-pA,0) difference. Study of the curves shows that there is no sharp dividingline between competitive and non-competitive antagonist action. Some drugs may act competitively at lower concentrations, but become non-competitive at higher concentrations. This is not surprising, since most competitive antagonists of plain muscle agonists such as acetylcholine also have a direct spasmolytic effect at higher concentrations. A transition from competitive to non-competitive would therefore be expected as antagonist concentration is increased, being especially apparent in the less potent compounds in which the margin between the two types of action is narrow. Such an effect might account for the discrepancies between the (pA2-pA10) method and the concentration-response curve method for assessing type of antagonism in the new phenothiazine compounds. On the other hand, the discrepancy between results with the (pA2-pA,0) method and concentration-response curves in the case of hyoscine, atropine and ethopropazine, in which there is a wide margin between specific anti-acetylcholine and general spasmolytic potencies, cannot be so explained. The apparent non-competitive nature of atropine when assessed by the (pA2-pA10) method has been described previously by Marshall (1955b) and was ascribed to the racemic nature of atropine, being a mixture of (+)-and (-)-hyoscyamine, the former appearing to be non-competitive and the latter competitive by the (pA2-pA10) method. The results of Timms (1956) and those in the present work using the concentration-response curve method suggest that the action of atropine over a wide range of concentrations is competitive, and this is also true of (+)-hyoscyamine (Marshall, unpublished observations ). An alternative explanation of this discrepancy might lie in the suggestions of Ariens & van Rossum (1957) that the difference between pA2 and pA10 can also depend upon the ratio of the number of molecules of receptor and antagonist combining together.
Of the compounds studied, only chlorpromazinre has shown a consistently noncompetitive anti-acetylcholine action by both methods of assessment. All the other compounds exhibited competitive antagonism to acetylcholine action over some, at least, of the range of concentrations used. The most potent acetylcholine antagonists were those drugs which are used for Parkinsonism in man, and, within this group, there was a significant correlation (P<0.01) between anti-acetylcholine potency and ability to antagonize experimental tremors in mice produced by Tremorine. This relationship does not necessarily hold for other tremor-producing drugs. For instance, atropine, hyoscine, diethazine, benzhexol and caramiphen, in doses up to 20 mg/kg in mice, had no effect on tremors induced by the aminoalcohol 3-amino-1,1,3-triphenylpropan-1-ol (compound no. 6, Ahmed, Marshall & Shepherd, 1958) . Again, when anti-tremor potencies were determined against harmine-induced tremors (Zetler, 1957) , these differed in order of potency from (Table 5 ). There appears to be a relation between anti-acetylcholine potency and antiParkinsonian activity in human beings on the one hand and between anti-acetylcholine potency and anti-Tremorine action in mice on the other. That this latter 253 A. AHMED and P. B. MARSHALL relationship applies only when tremor is induced with Tremorine confirms the previous conclusions of Everett, Blockus, Shepperd & Toman (1956 ) that this agent is particularly suitable for the experimental evaluation of drugs for anti-Parkinsonian action. The correlation of anti-tremor and anti-Parkinsonian potency with antiacetylcholine potency provides further support for the view that the lesion in Parkinsonism is associated in some way with acetylcholine, possibly in the role of a central nervous system transmitter.
